Skip to main content
Fig. 3 | BMC Immunology

Fig. 3

From: Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients

Fig. 3

The forest plot of a overall survival (OS) and b progression-free survival (PFS) for ICIs-based versus non-ICIs-based therapy in pMMR/non-MSI-H mCRC; the forest plot of PFS for c ICIs plus anti-VEGF agent and chemotherapy versus non-ICIs-based therapy, and d RAS wild type (wt) versus RAS mutant type (mt) in pMMR/non-MSI-H mCRC

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us